Vinge Logotype
Svenska English 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Ottobock on its acquisition of Exoneural Network AB
Mandate

Vinge advises Ottobock on its acquisition of Exoneural Network AB

January 25, 2021 Employment and Benefits IT, Telecommunications and Outsourcing M&A Corporate Commercial Corporate Crime & Compliance

Vinge advises Ottobock, a portfolio company to EQT, on its acquisition of Exoneural Network AB a Swedish startup that has developed the so called Exopulse Mollii Suit.

The suit covers the entire body and uses electrostimulation to relax tense or spastic muscles which can improve the mobility for people with spastic diseases. Ottobock is an international medtech company and the acquisition is a step towards the expansion of its portfolio for promising neuro-orthotics.

Vinge’s team consisted of, among others, partner Christina Kokko, associates Stina Bengtsson, Jesper Lindvall and Annie Fällström (M&A), Sara Strandberg and Carl Östlund (Employment), Stojan Arnerstål och Sofia Bergenstråhle (IP), Mika Jordan (IT & GDPR), Christoffer Nordin (Regulatory) Fredrika Hjelmberg and Carla Zachariasson (Commercial Agreements) Tove Lövgren Frisk (Compliance) and Carl Bruneheim (Project assistant).

Related

Vinge advises Axcel VI and Currentum in connection with the acquisition of Elprojekt Skandinavien

 Vinge advises Axcel VI and the Currentum Group in connection with the acquisition of Elprojekt Skandinavien. The company provides complete electrical installations throughout Sweden, focusing on new construction of logistics properties, production facilities, residential buildings and office buildings. Elprojekt Skandinavien had a revenue of SEK 316 million in 2024.
June 23, 2025

Vinge advises Meribel Pharma Solutions

 Vinge advises Meribel Pharma Solutions in connection with the sale of a production facility specialising in the manufacture of antibiotics to Apotek Produktion & Laboratorier AB ("APL").
June 23, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 232 million and restructuring of debt financing

 Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue, through which Hansa raises gross proceeds of approx. SEK 232 million, and restructuring of debt financing. As part of such debt restructuring, Hansa has in conjunction with the directed share issue set-off debt corresponding to approximately USD 14.9 million of its total debt amount.
June 23, 2025